I have recently posted on the promotion of Lurasidone (Latuda) in the UK. This has raised concerns for me about transparency of conflicts of interest for some of the key doctors and academics involved with the research, development and promotion of this novel antipsychotic.
One of those who has most significant financial interests is Professor Stephen Stahl. In “partnership with” the British Association for Psychopharmacology he recently gave this “Expert Seminar” at the University of Bristol:
This “Expert Seminar” is introduced by Professor Stahl as follows:
“Application” was made by Sunovion for CPD approval to the Federation of the Royal College of Physicians of the United Kingdom.
This “robust learning environment for UK health professionals” has left me asking some questions:
- Were the healthcare professionals made…
View original post 95 more words